Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study
Identifieur interne : 001802 ( PascalFrancis/Curation ); précédent : 001801; suivant : 001803Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study
Auteurs : Yoshikuni Mizuno [Japon] ; Takashi Abe [Japon] ; Kazuko Hasegawa [Japon] ; Sadako Kuno [Japon] ; Tomoyoshi Kondo [Japon] ; Mitsutoshi Yamamoto [Japon] ; Mitsuyoshi Nakashima [Japon] ; Ichiro Kanazawa [Japon]Source :
- Movement disorders [ 0885-3185 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. - 1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off' was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001517
Links to Exploration step
Pascal:08-0015784Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Abe, Takashi" sort="Abe, Takashi" uniqKey="Abe T" first="Takashi" last="Abe">Takashi Abe</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Iwate Medical University</s1>
<s2>Morioka</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Hospital Organization, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Clinical Research, National Hospital Organization, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Wakayama Medical University</s1>
<s2>Wakayama</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Kagawa Prefectual Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Nakashima, Mitsuyoshi" sort="Nakashima, Mitsuyoshi" uniqKey="Nakashima M" first="Mitsuyoshi" last="Nakashima">Mitsuyoshi Nakashima</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Clinical Pharmacology, Hamamatsu Institute of Clinical Pharmacology and Therapeutics</s1>
<s2>Hamamatsu</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kanazawa, Ichiro" sort="Kanazawa, Ichiro" uniqKey="Kanazawa I" first="Ichiro" last="Kanazawa">Ichiro Kanazawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0015784</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0015784 INIST</idno>
<idno type="RBID">Pascal:08-0015784</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001517</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001802</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Abe, Takashi" sort="Abe, Takashi" uniqKey="Abe T" first="Takashi" last="Abe">Takashi Abe</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Iwate Medical University</s1>
<s2>Morioka</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Hospital Organization, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Clinical Research, National Hospital Organization, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Wakayama Medical University</s1>
<s2>Wakayama</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Kagawa Prefectual Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Nakashima, Mitsuyoshi" sort="Nakashima, Mitsuyoshi" uniqKey="Nakashima M" first="Mitsuyoshi" last="Nakashima">Mitsuyoshi Nakashima</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Clinical Pharmacology, Hamamatsu Institute of Clinical Pharmacology and Therapeutics</s1>
<s2>Hamamatsu</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kanazawa, Ichiro" sort="Kanazawa, Ichiro" uniqKey="Kanazawa I" first="Ichiro" last="Kanazawa">Ichiro Kanazawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du système nerveux</term>
<term>Maladie de Parkinson</term>
<term>Ropinirole</term>
<term>Lévodopa</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. - 1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off' was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MIZUNO (Yoshikuni)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ABE (Takashi)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HASEGAWA (Kazuko)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KUNO (Sadako)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KONDO (Tomoyoshi)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>YAMAMOTO (Mitsutoshi)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>NAKASHIMA (Mitsuyoshi)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KANAZAWA (Ichiro)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Iwate Medical University</s1>
<s2>Morioka</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, National Hospital Organization, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Clinical Research, National Hospital Organization, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Wakayama Medical University</s1>
<s2>Wakayama</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Kagawa Prefectual Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Clinical Pharmacology, Hamamatsu Institute of Clinical Pharmacology and Therapeutics</s1>
<s2>Hamamatsu</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>STRONG Study Group</s1>
<s3>JPN</s3>
</fA17>
<fA20><s1>1860-1865</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000173554140030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0015784</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. - 1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off' was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001802 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001802 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:08-0015784 |texte= Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study }}
This area was generated with Dilib version V0.6.23. |